

Special Issue

Enterovirus Vaccines Development and Immune Responses Following Immunization

Message from the Guest Editors

Currently, no effective vaccine is available against enteroviruses except for poliovirus and EV-A71. Although the EV-A71 vaccine has provided a powerful tool for containing HFMD outbreaks, cross-protection against other HFMD-associated enteroviruses has been very limited. Moreover, as the causative spectrum of HFMD has shifted, the prevalence of CVA6, CVA10, and CVA16 has significantly surpassed that of EV-A71. Therefore, vaccines against other pathogens urgently need to be developed. This Special Issue is intended to cover past and ongoing efforts to develop vaccines against enteroviruses. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but they are not limited to) the following: enterovirus vaccine development; immune efficacy of enterovirus vaccines; and challenges in enterovirus vaccine development.

Guest Editors

Dr. Yuefei Jin

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China

Dr. Shuaiyin Chen

College of Public Health, Zhengzhou University, Zhengzhou 450001, China

Deadline for manuscript submissions

closed (28 February 2026)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/204785

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).